GT Biopharma公布Gtb-3650一期临床试验入组更新，试验针对复发或难治性CD33阳性血液恶性肿瘤患者

美股速递2025-10-08

GT Biopharma Inc.近日发布了其Gtb-3650一期临床试验的入组进展更新。该试验专门针对患有复发或难治性CD33表达血液恶性肿瘤的患者群体。

此次试验更新显示了公司在血液肿瘤治疗领域的持续推进，为那些对传统治疗方案产生抗药性或疾病复发的患者提供新的治疗选择。CD33是一种在某些血液癌症细胞表面表达的蛋白质，成为靶向治疗的重要标靶。

GT Biopharma通过这一试验更新，展现了其在开发创新癌症疗法方面的进展，特别是针对难治性血液系统恶性疾病的治疗突破。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1106596336?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-08 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106596336","market":"us","top_or_hot":-1,"title":"GT Biopharma公布Gtb-3650一期临床试验入组更新，试验针对复发或难治性CD33阳性血液恶性肿瘤患者","media":"美股速递","content":"<p>GT Biopharma Inc.近日发布了其Gtb-3650一期临床试验的入组进展更新。该试验专门针对患有复发或难治性CD33表达血液恶性肿瘤的患者群体。</p>\n<p>此次试验更新显示了公司在血液肿瘤治疗领域的持续推进，为那些对传统治疗方案产生抗药性或疾病复发的患者提供新的治疗选择。CD33是一种在某些血液癌症细胞表面表达的蛋白质，成为靶向治疗的重要标靶。</p>\n<p>GT Biopharma通过这一试验更新，展现了其在开发创新癌症疗法方面的进展，特别是针对难治性血液系统恶性疾病的治疗突破。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GT Biopharma公布Gtb-3650一期临床试验入组更新，试验针对复发或难治性CD33阳性血液恶性肿瘤患者</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGT Biopharma公布Gtb-3650一期临床试验入组更新，试验针对复发或难治性CD33阳性血液恶性肿瘤患者\n</h2>\n\n<h4 class=\"meta\">\n\n2025-10-08 21:02 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GT Biopharma Inc.近日发布了其Gtb-3650一期临床试验的入组进展更新。该试验专门针对患有复发或难治性CD33表达血液恶性肿瘤的患者群体。\n此次试验更新显示了公司在血液肿瘤治疗领域的持续推进，为那些对传统治疗方案产生抗药性或疾病复发的患者提供新的治疗选择。CD33是一种在某些血液癌症细胞表面表达的蛋白质，成为靶向治疗的重要标靶。\nGT Biopharma通过这一试验更新，展现了其...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1106596336","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106596336","pubTimestamp":1759928523,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GT Biopharma Inc.近日发布了其Gtb-3650一期临床试验的入组进展更新。该试验专门针对患有复发或难治性CD33表达血液恶性肿瘤的患者群体。\n此次试验更新显示了公司在血液肿瘤治疗领域的持续推进，为那些对传统治疗方案产生抗药性或疾病复发的患者提供新的治疗选择。CD33是一种在某些血液癌症细胞表面表达的蛋白质，成为靶向治疗的重要标靶。\nGT Biopharma通过这一试验更新，展现了其在开发创新癌症疗法方面的进展，特别是针对难治性血液系统恶性疾病的治疗突破。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","GTBP":"GT Biopharma Inc."},"translate_title":"GT Biopharma announces the enrollment update of the Phase I clinical trial of Gtb-3650, which targets patients with relapsed or refractory CD33-positive hematological malignancies","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GTBP":1},"content_text":"GT Biopharma Inc.近日发布了其Gtb-3650一期临床试验的入组进展更新。该试验专门针对患有复发或难治性CD33表达血液恶性肿瘤的患者群体。\n此次试验更新显示了公司在血液肿瘤治疗领域的持续推进，为那些对传统治疗方案产生抗药性或疾病复发的患者提供新的治疗选择。CD33是一种在某些血液癌症细胞表面表达的蛋白质，成为靶向治疗的重要标靶。\nGT Biopharma通过这一试验更新，展现了其在开发创新癌症疗法方面的进展，特别是针对难治性血液系统恶性疾病的治疗突破。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106596336","isCrawlerRequest":true}